Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine attenuation of rosuvastatin protection against forearm ischemia-reperfusion injury
NL-OMON30751Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, caffeine in ischemia-reperfusion injury (IRI), myocardial infarction (MI), sponsored by Radboud University Medical Center. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
rosuvastatincaffeine
03
Conditions
ischemia-reperfusion injury (IRI)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON30751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30751.